Pharmacokinetic Aspects of the Onset of Action of Neuromuscular Blocking Agents

Literatur

• 1 Sheiner L B, Stanski D R, Vozeh S, Miller R D, Ham J. Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d-tubocurarine.  Clin. Pharmacol. Ther.. 1979;  25 358-371
• 2 Donati F, Meistelman C. A kinetic-dynamic model to explain the relationship between high potency and slow onset time for neuromuscular blocking drugs.  J. Pharmacokinet. Biopharm.. 1991;  19 537-552
• 3 Proost J H, Wierda J MKH, Meijer D KF. An extended pharmacokinetic/pharmacodynamic (PK/PD) model describing quantitatively the influence of plasma protein binding, tissue binding, and receptor binding on the potency and time course of action of drugs.  J. Pharmacokinet. Biopharm.. 1996;  24 45-77
• 4 Wierda J MKH, Proost J H, Muir A W, Marshall R J. Design of drugs for rapid onset.  Anaesth. Pharmacol. Rev.. 1993;  1 57-68
• 5 Beaufort T M, Nigrovic V, Proost J H, Houwertjes M C, Wierda J MKH. Inhibition of the enzymic degradation of suxamethonium and mivacurium increases the onset time of submaximal neuromuscular block.  Anesthesiology. 1998;  89 707-714
• 6 Bowman W C, Rodger I W, Houston J, Marshall R J, McIndewar I. Structure: action relationships among some desacetoxy analogues of pancuronium and vecuronium in the anesthetized cat.  Anesthesiology . 1988;  69 57-62
• 7 Kopman A F. Pancuronium, gallamine, and d-tubocurarine compared - is speed of onset inversely related to drug potency.  Anesthesiology. 1989;  70 915-920
• 8 Armstrong D L, Lester H A. The kinetics of tubocurarine action and restricted diffusion within the synaptic cleft.  J. Physiol. (Lond). 1979;  294 365-386